New opportunities of using gialuronidase in chronic prostatitis


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Introduction. The use of hyaluronidase contributes to improvement in microcirculation, destruction of biofilms and reducing of congestion in patients with chronic prostatitis. Based on this mechanism, the use Longidaza* for the diagnosis of latent bacterial prostatitis was suggested. Aim. To evaluate diagnostic and treatment capabilities of the long-acting enzyme preparation Longidaza* (rectal suppositories with an activity of 3000 IU), prescribed to patients with chronic prostatitis in routine clinical practice. Materials and methods. A total of 39 men with chronic prostatitis of categories II and IIIa were included in open, prospective, noninterventional, comparative, single-center study. A microbiological study of expressed prostate secretion (EPS) was performed three times, at baseline, after using two suppositories Longidaza 3000 IU and after 7 weeks of therapy. From the 1st to the 10th suppository, Longidaza* was used every 48 hours, then, from the 11th to the 20th suppository, it was prescribed every 72 hours. The isolation of the pathogen was an indication for the antibiotic therapy. The treatment outcome was evaluated by using NIH-CPSI scale and laboratory and microbiological analysis of EPS. Results. Diagnostic stage. Initially, pathogens were isolated in 27 (69.2%) patients. The number of leukocytes in EPS averaged 25.9±2.3. The use of two suppositories Longidaza* increased the number of patients with isolated pathogens to 33 (82%). In 7 out 12 patients with an initial diagnosis of abacterial prostatitis, the use of two suppositories of Longidaza* contributed to isolation of the pathogen in EPS (58.3%). The number of leukocytes in the EPS after enzymatic provocation increased by 50.2%. Treatment stage. The number of patients with isolated pathogens decreased from 33 to 7 (17.9%). The pain intensity decreased on average to 2.2±0.4 points, and in 27 (69.2%) men dysuria resolved. The quality of life significantly improved up to 1.3±0.2 points. The total score on NIH-CPSI scale decreased on average from 17.3±1.9 to 3.9±0.3 (p<0.05). An increased number of white blood cells in EPS was seen only in 5 (12.8%) men. Conclusion. In many cases, bacterial prostatitis remains undiagnosed. Rectal suppositories Longidaza* can be recommended for the diagnosis of the latent bacterial chronic prostatitis, since this drug contributes to detection of pathogen and inflammation.

Full Text

Restricted Access

About the authors

E. V Kulchavenya

TB Research Institute of Ministry of Health of Russia; MC “BIOVER”

Email: urotub@yandex.ru
MD, professor, Chief Scientist at TB Research Institute of Ministry of Health of Russia; Head of the Department of Urology, professor at Department of Tuberculosis of Novosibirsk State Medical University of Ministry of Health of Russia Novosibirsk, Russia

S. Yu Shevchenko

TB Research Institute of Ministry of Health of Russia

Email: urotub@yandex.ru
Ph.D., senior researcher at TB Research Institute of Ministry of Health of Russia Novosibirsk, Russia

A. G Cherednichenko

TB Research Institute of Ministry of Health of Russia

Email: urotub@yandex.ru
Head of the Microbiological laboratory of TB Research Institute of Ministry of Health of Russia Novosibirsk, Russia

A. A Breusov

MC “BIOVER”

Ph.D., director Novosibirsk, Russia

A. A Vinitskiy

LTD «NPO “Petrovax Pharm”

Email: VinitskiyAA@petrovax.ru
Ph.D., medical advisor, medical department Moscow, Russia

References

  1. Коган М.И., Набока Ю.Л., Исмаилов Р.С., Белоусов И.И., Гудима И.А. Бактериальный простатит: эпидемиология и этиология. Урология 2018;6:144-148
  2. Кульчавеня Е.В., Холтобин Д.П., Шевченко С.Ю., Потапов В.В., Зулин Я.В. Частота хронического простатита в структуре амбулаторного урологического приема. Экспериментальная и клиническая урология.2015;1:16-19
  3. Mazzoli S. Biofilms in chronic bacterial prostatitis (NIH-II) and in prostatic calcifications. FEMS Immunology & Medical Microbiology. 2010;59(3):337-344.
  4. Polackwich A.S., Shoskes D.A. Chronic prostatitis/chronic pelvic pain syndrome: a review of evaluation and therapy. Prostate Cancer Prostatic Dis 2016;19(2):132-138.
  5. Weidner W., Diemer T., Wagenlehner F. Male urogenital infections. Clinical Uro-Andrology. Ed.: V. Mirone. Springer-Verlag Berlin Heidelberg, 2015. P. 205-212.
  6. Franco J.V.A, Turk T., Jung J.H., Xiao Y.T., Iakhno S., Tirapegui F.I., Garrote V., Vietto V. Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome: a Cochrane systematic review. BJU Int. 2020 Jan 3. doi: 10.1111/bju.14988.
  7. Филимонов П.Н., Кульчавеня Е. В. Последствия избыточного формирования фиброза у больных хроническим простатитом. РМЖ.2019;27(2):39-41.
  8. Кульчавеня Е.В., Швецова О.П., Бреусов А.А. Обоснование назначения и эффективность препарата Лонгидаза у больных хроническим простатитом. Урология 2018;4:64-71). Doi: https://dx.doi.org/10.18565/urology.2018.4:64-71.
  9. Зайцев А.В., Пушкарь Д.Ю., Ходырева Л.А., Дударева А.А. Хронический бактериальный простатит, расстройства мочеиспускания у мужчин и фиброз предстательной железы. Урология. 2016;4:114-121.
  10. Коган М.И., Набока Ю.Л., Тодоров С.С., Исмаилов Р.С. Экспериментальная оценка течения воспалительного процесса в простате при ее трансуретральном инфицировании низким титром уропатогена. Урология. 2019;5:14-21.
  11. Murphy S.F., Hall C., Done J.D., Schaeffer A.J., Thumbikat P. A prostate derived commensal Staphylococcus epidermidis strain prevents and ameliorates induction of chronic prostatitis by UPEC infection. Sci Rep. 2018;8(1):17420. doi: 10.1038/s41598-018-35818-1.
  12. Цуканов А.Ю., Сатыбалдин Д.О., Семикина С.П. Повышение результативности микробиологического исследования эякулята при диагностике причин мужского бесплодия. Урология. 2019;6:26-30.
  13. Байдамшина Д.Р., Тризна Е.Ю., Виницкий А.А., Каюмов А.Р. Изолированное и сочетанное с антибактериальными средствами влияние бовгиалуронидазы азоксимер на целостность бактериальной биопленки и жизнеспособность микроорганизмов в ней in vitro. Экспериментальная и клиническая фармакология. 2020;83:38-44.
  14. Wagenlehner F., Tandogdu Z., Bartoletti R., Cai T., Cek M, Kulchavenya E., Koves B., Naber K., Perepanova T., Tenke P., Wullt B., Bogenhard F. and Bjerklund Johansen T.E. The Global Prevalence of Infections in Urology Study: A Long-Term, Worldwide Surveillance Study on Urological Infections. Pathogens 2016;5:1-8. doi: 10.3390/pathogens5010010
  15. Палагин И.С., Сухорукова М.В., Дехнич А.В., Эйдельштейн М.В., Перепанова Т.С., Козлов Р.С. исследовательская группа «ДАРМИС-2018». Антибиотикорезистентность возбудителей внебольничных инфекций мочевых путей в России: результаты многоцентрового исследования «ДАРМИС-2018». КМАХ. 2019;21 (2): 134-146). Doi: https://doi. org/10.36488/cmac.2019.2.134-146
  16. Maurizi A., De Luca F., Zanghi A., Manzi E., Leonardo C., Guidotti M., Antonaccio F.P., Olivieri V., De Dominicis C. The role of nutraceutical medications in men with non bacterial chronic prostatitis and chronic pelvic pain syndrome: A prospective non blinded study utilizing flower pollen extracts versus bioflavonoids. Arch Ital Urol Androl. 2019;90(4):260-264. doi: 10.4081/aiua.2018.4.260.
  17. Almeida F., Santos Silva A., Silva Pinto A., Sarmento A. Chronic prostatitis caused by extended-spectrum p-lactamase-producing Escherichia colimanaged using oral fosfomycin-A case report. IDCases. 2019;15:e00493. doi: 10.1016/j.idcr.2019.e00493.
  18. Zhanel G.G., Zhanel M.A., Karlowsky J.A. Oral Fosfomycin for the Treatment of Acute and Chronic Bacterial Prostatitis Caused by Multidrug-Resistant Escherichia coli. Can J Infect Dis Med Microbiol. 2018;2018:1404813. doi: 10.1155/2018/1404813.
  19. Виноградов И.В., Ким Д.Г. Способ лечения хронического калькулезного простатита. Патент на изобретение RU 2534853 С1б 10.12.2014). Поступила 10.03.2020

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies